Microbial therapeutics: New opportunities for drug delivery
Miguel Jimenez, R. Langer, G. Traverso
AI summary
100% confidenceMES research with healthcare focus on medical. With >40 clinical trials underway, we are nearing the first FDA-approved live microbial therapeutic. Here, Giovanni Trav...
Generated by MESSAI extraction pipeline · review against source PDF
Reported parameters
No values extracted from this paper yet.
No 3D model is mapped to this paper yet. Parameter ranges above still place reported values on the literature distribution.
Abstract
With >40 clinical trials underway, we are nearing the first FDA-approved live microbial therapeutic. Here, Giovanni Traverso, MIT and Harvard Medical School Assistant Professor, and colleagues Miguel Jimenez and Institute Professor Robert Langer from MIT discuss the significant challenges of administering live microorganisms to patients and the opportunities for drug delivery of these new complex therapeutics.
Keywords
Identifiers
- Journal
- Journal of Experimental Medicine
- Year
- 2019